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Abstract
Astroglia are key cellular sites where opiate drug signals converge with the proinflammatory effects of HIV-1 Tat signals to
exacerbate HIV encephalitis. Despite this understanding, the molecular sites of convergence driving opiate-accelerated
neuropathogenesis have not been deciphered. We therefore explored potential points of interaction between the signaling
pathways initiated by HIV-1 Tat and opioids in striatal astrocytes. Profiling studies screening 152 transcription factors
indicated that the nuclear factor-kappa B (NF-kB) subunit, c-Rel, was a likely candidate for Tat or Tat plus opiate-induced
increases in cytokine and chemokine production by astrocytes. Pretreatment with the NF-kB inhibitor parthenolide
provided evidence that Tat6morphine-induced release of MCP-1, IL-6 and TNF-a by astrocytes is NF-kB dependent. The
nuclear export inhibitor, leptomycin B, blocked the nucleocytoplasmic shuttling of NF-kB; causing p65 (RelA) accumulation
in the nucleus, and significantly attenuated cytokine production in Tat6morphine exposed astrocytes. Similarly, chelating
intracellular calcium ([Ca
2+]i) blocked Tat6morphine-evoked MCP-1 and IL-6 release, while artificially increasing the
concentration of extracellular Ca
2+ reversed this effect. Taken together, these results demonstrate that: 1) exposure to
Tat6morphine is sufficient to activate NF-kB and cytokine production, 2) the release of MCP-1 and IL-6 by Tat6morphine
are highly Ca
2+-dependent, while TNF-a appears to be less affected by the changes in [Ca
2+]i, and 3) in the presence of Tat,
exposure to opiates augments Tat-induced NF-kB activation and cytokine release through a Ca
2+-dependent pathway.
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Introduction
Among human immunodeficiency virus type 1 (HIV-1)-infected
individuals, injection drug users are at greater risk than nonusers of
developing HIV-associated neurological impairment, as well as
other opportunistic infections [1–3]. Not only does injection drug
use provide a mode for viral spread, but the opioid system (i.e.,
endogenous opioid peptides and receptors) also plays a fundamental
role in modifying, and in many cases exacerbating the pathogenesis
of neuro-acquired immune deficiency syndrome (neuroAIDS) [4–
6]. Brain regions expressing a high number/density of m-opioid
receptors (MOP), such as the striatum and the hippocampus, have
increased viral loads and are preferentially decimated by HIV
infection (reviewed in [4–6]). Therefore, the central nervous system
(CNS) may be uniquely susceptible to the combined effects of opiate
substance abuse and HIV-1. m-Opioid receptor-expressing astro-
cytes in particular may be an important site of convergence for
opiate drug-HIV-1 actions. Previously, we and others have shown
that opiatesexacerbatetheastroglialresponsetoHIV-1proteins[7–
9], causing increased disruptions in [Ca
2+]i homeostasis and
increased chemokine release. However, the mechanisms underlying
opiate-induced increases of chemokine expression and release in
astrocytes exposed to HIV-1 protein are incompletely understood.
Astrocytes are essential in regulating neuronal function and
support, and participate in neurogenesis [10], synaptic transmis-
sion [11], brain repair [12], and in the formation and preservation
of the blood-brain barrier [13]. When brain homeostasis is
disrupted, astrocytes become activated, producing a variety of
factors, including nitric oxide, neuropeptides and cytokines
[14,15]. Astrocytes are a major source of cytokines (e.g., TNF-a
and IL-1b) and chemokines (e.g., CCL2/MCP-1, CCL5/
RANTES, and CCL3/MIP-1 a) in the HIV-1 infected CNS
[14,16]. Opiates act by exacerbating the astroglial response to
HIV-1 [17], which involves the release of cytokines and
chemokines, the recruitment of macrophages and activated
microglia, and an amplification of the inflammatory response [18].
MCP-1, IL-6 and TNF-a are involved in the induction and
perpetuation of innate immune and inflammatory responses.
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e4093MCP-1 is a potent chemokine and is thought to be involved in the
progression of neuroAIDS and HIV associated dementia by virtue
of its ability to recruit and activate macrophages/microglia
[19,20]. MCP-1 appears to play a central role in promulgating
neuroimmune disease processes within the CNS, as recent
evidence indicates that MCP-1 levels are highly correlated with
neurocognitive defects accompanying HIV-1 [21,22]. Similarly,
IL-6 and TNF-a are elevated in the central nervous system of
individuals with AIDS or AIDS dementia complex [23]. IL-6 can
upregulate production of HIV in infected monocytic cells and IL-6
can act synergistically with TNF-a [24]. Importantly, depending
on concentration, morphine can significantly increase or decrease
lipopolysaccharide-induced NF-kB transcriptional activity in
murine macrophages, which is directly proportional to TNF-a
and IL-6 release [25]. In light of evidence that the pattern of
cytokine release in response to Tat and/or morphine differs in
macrophages and astroglia [17], and since NF-kB along with other
transcription factors induce the production of MCP-1, IL-6 and
TNF-a by astrocytes [26–28], we were prompted to explore
whether NF-kB was differentially regulated by Tat6morphine in
astrocytes and determine whether opiates are acting via NF-kBt o
modulate cytokine production by HIV-1 Tat exposed astrocytes.
NF-kB is an essential transcription factor that plays a central
role in the regulation of genes involved in the immune and
inflammatory responses [29–31]. NF-kB is also involved in
development, cell proliferation, apoptosis, signaling injury, synap-
tic transmission, neuronal plasticity, and neurodegenerative
diseases [32,33]. The NF-kB family is comprised of five members,
RelA (p65), RelB, c-Rel, p105/p50, and p100/p52. All share the
Rel homology domain, which allows their dimerization and
translocation to the nucleus. Association with IkB, an inhibitor of
NF-kB, tightly regulates the activity of NF-kB. NF-kB is inactive
and retained in the cytoplasm when bound to the IkB proteins.
However, NF-kB activation triggers events that generally result in
(1) the polyubiquitination and degradation of IkB, (2) the
unmasking of nuclear localizing signals (NLS), (3) the translocation
of unbound NF-kB molecules to the nucleus where they modulate
the transcription of specific genes [34,35]. In the present study, we
examined mechanisms by which opioids influence NF-kB
signaling pathways and whether this regulates inflammatory gene
activity in astrocytes exposed to HIV-1 proteins. Data presented
here show how opioids modulate the regulatory mechanisms
involved in the secretion of cytokines IL-6 and TNF-a, and in
particular the production of the chemokine, MCP-1.
Materials and Methods
Materials
RPMI 1640 was purchased from Gibco (Grand Island, NY).
Morphine sulfate was obtained from the National Institute on
Drug Abuse (NIDA, Drug Supply System, Bethesda, MD). Tat1–72
recombinant protein was produced at the University of Kentucky
Tat core facility. The NF-kB inhibitor, parthenolide, and the IkB
inhibitor, Ro106-9920, were purchased from Sigma (St. Louis,
MO), while leptomycin B (LMB) was purchased from LC
Laboratories (Woburn, MA). Antibodies directed against b-actin,
and p65 (RelA) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA), and used for immunoblotting or immunocyto-
chemistry.
Cell Culture
Astroglial-enriched cultures were prepared using 1–4-day-old
ICR mice (Charles River Laboratories, Charles River, MA) as
previously described [36]. Briefly, mice were anesthetized and
euthanized according to NIH and IACUC guidelines, which
minimizes the number of animals used and their discomfort. Striata
were aseptically isolated, minced in media, incubated with trypsin/
DNase (37uC, 30 min), triturated through a series of decreasing
bore pipettes, and filtered sequentially through 130 mm pore nitex
filters. Cells for each experiment were pooled from two to four
striata. Growth medium favoring astroglial enrichment consisted of
Dulbecco’s Modified Eagle’s Medium (DMEM) (GIBCO) supple-
mented with glucose (27 mM), Na2HCO3 (6 mM), HEPES
(10 mM), and 10% (v/v) fetal bovine serum (FBS; JRH Biosciences
orHyclone,Logan,UT).Cellswereplated at50,000–100,000cells/
cm
2 in poly-L-lysine-coated 12 or 24-well plates for protein
detection (Costar, Corning Life Sciences, Acton, MA), or in
100 mm culture dishes for transcription factor assays. Cells were
grownfor7–10 daysuntiltheyreached 70–80%confluencyat37uC
in 5% CO2/95% air at high humidity. Cultures consisted of .98%
astrocytes as determined by staining for glial fibrillary acidic protein
(GFAP). Unless mentioned elsewhere, cell culture products were
purchased from Invitrogen (Gaithersburg, MD).
Experimental Treatments
Recombinant Tat1–72 was produced and purified as described
previously [17]. Briefly, the tat gene encoding the first 72 amino
acids of HIV-1BRU (obtained from Dr. Richard Gaynor, through
the NIH AIDS repository) was inserted into an Escherichia coli Pin
Point Xa-2 vector (Promega, Madison, WI). Biotinylated Tat was
purified on a column of soft release avidin resin, cleaved from the
fusion protein using factor Xa, eluted and desalted using a PD10
column, and treated with Pierce Detoxi-Gel (Pierce). A reticulo-
cyte amoebocyte lysate assay is used to assay for trace endotoxin
(Associates of Cape Cod, Inc.; sensitivity,1 pg/ml). If endotoxin
is detected, the Tat is discarded. Cytokine release was not observed
in astrocytes treated with non-toxic, deletion mutant Tat (TatD31–
61) or immunoneutralized Tat [9,17].
Cells were continuously exposed to medium alone (vehicle-
treated controls), morphine sulfate and/or Tat1–72 for varied
intervals. The concentrations of morphine and Tat1–72 were
500 nM and 100 nM, respectively. Multiple concentrations of
inhibitors were initially screened as part of the intracellular
calcium studies [17,37]. For each inhibitor, the initial range of
concentrations screened was based on published values. Parthe-
nolide (0, 1, 5, 10 and 20 mM) was used to inhibit NF-kB
activation. BAPTA/AM (0, 1, 5, 10 and 20 mM) was used to
chelate calcium. Leptomycin B (0, 1, 5, 10 and 20 nM) has been
shown by others to prevent export of proteins from nucleus to
cytoplasm, while Ro106-9920 (0, 1, 5, 10 and 20 mM) has been
shown to inhibit proteasome activity and IkBa degradation. For
some experiments, inhibitors were added to cell cultures and
preincubated for 15–20 min at 37uC (5% CO2/95% air), followed
by 6, 12 and 24 h of continuous incubation with Tat6morphine
as previously described [17].
Transcription Factor Arrays
We used TranSignal
TM Protein/DNA Arrays I & II (Panomics
Inc., Redwood City, CA) to screen for potential changes in
activation of a wide spectrum of transcription factors due to
Tat6morphine exposure. Astrocytes were harvested after 4 or
24 h treatment. Nuclear extracts of control and treated astrocytes
were prepared using a Nuclear Extraction Kit (Panomics) and
were incubated with a biotin-labeled, DNA-binding oligonucleo-
tide probe mixture (15uC for 30 min) provided with the array kit
to allow formation of transcription factor-DNA complexes.
Complexes were isolated on a 2% agarose gel. Probes were then
separated from transcription factors and hybridized to TranSignal
Opioids HIV Glial Inflammation
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the DNA probes in the mixture. HRP chemiluminescence
detection was used to visualize biotinylated sequences bound to
each array. A Kodak Image Station 440CF with 1-D software was
used for densitometric quantitation of transcription factor levels.
Real-Time PCR
For real-time RT-PCR, total RNA was isolated from treated cells
using GenElute
TM Mammalian Total RNA kit (Sigma). cDNA was
synthesized from 2 mg of total RNA using a High-Capacity cDNA
Archive Kit (Applied Biosystems, Warrington, UK). Standards
containing varying concentrations of cDNA templates (cDNA mix
and 26,4 6,8 6,1 6 6dilutions) were used to generate a standard
curve. TaqMan Universal PCR Master Mixes and gene-specific
TaqMan probes and primer sets for MCP-1 and 18S rRNA was
purchased from Applied Biosystems. Real time RT-PCR was
conducted usingthePrism7500 system (Applied Biosystems).MCP-
1 mRNA was normalized to 18S mRNA. Primers for IL-6 and
TNF-a were purchased from Integrated DNA technologies (IDT)
and normalized to b-actin mRNA.
Electrophoretic Mobility Shift Assay (EMSA)
All procedures for nuclear protein extraction were performed at
4uC with ice-cold reagents. Cells were gently scraped in PBS,
washed, and resuspended in 500 ml of lysis buffer A [15 mM KCl,
10 mM HEPES, 2 mM MgCl2, 0.1 mM EDTA, 1 mM PMSF,
1 mM dithiothreitol (DTT), 10 mg/ml aprotinin, 2 mg/ml leu-
peptin, 0.1% NP-40, pH 7.6]. Cell suspensions were then
incubated for 10–15 min on ice with occasional vortexing, and
centrifuged for 30 s to pellet the nuclei. Pelleted nuclei were rinsed
with wash buffer B (2 mM KCl, 25 mM HEPES, 0.1 mM EDTA,
1 mM PMSF, 1 mM DTT, 10 mg/ml aprotinin, 2 mg/ml
leupeptin, pH 7.6) and incubated at 4uC for 20 min. Nuclear
extracts were then prepared by centrifugation at 20,0006 g for
15 min in buffer C (25 mM HEPES, 0.1 mM EDTA, 20%
glycerol, pH 7.6) and stored at 280uC until used for EMSA. The
probe containing NF-kB-binding element was labeled with c-[
32P]
(Amersham Life Science) (3000 Ci/mmol, 250 mCi) using T4
polynucleotide kinase (Boehringer Mannheim). 10 mg of extracts
was incubated for 20 min with 20,000 cpm of [
32P]-labeled
double-stranded oligonucleotide at 4uCi na2 5 ml reaction
mixture containing: 10 mg/ml BSA, 106 buffer D (100 mM
KCl, 20 mM HEPES, 0.5 mM EDTA, 2 mM DTT, 0.1 mM
PMSF, 20% glycerol, 0.25% NP-40, pH 7.6), 56 buffer F
(300 mM KCl, 100 mM HEPES, 10 mM DTT, 100 mM PMSF,
20% Ficoll, pH 7.6) and 1 mg/ml poly(dI-dC). In competition
assays, 1006 cold NF-kB competitors were added. The DNA–
protein complex was separated on a non-denaturating 4%
polyacrylamide gel in TBE buffer (Tris-HCl, boric acid, EDTA
2 mM, pH 8.0). After electrophoresis, the gel was dried and
autoradiography performed by overnight exposure to X-ray film.
Western Immunoblotting
Cells were grown in 24-well plates and all procedures for protein
extraction were performed at 4uC with ice-cold reagents. Cells
were washed in cold PBS, scraped, harvested and disrupted in
RIPA buffer [16 PBS, 1% NP-40, 0.5% sodium deoxycholate,
0.1% SDS, plus protease inhibitor cocktail (Sigma)]. After 30–
60 min incubation on ice, cell lysate was centrifuged for 20 min
(15,0006 g, 4uC). The supernatant fluid was collected and the
protein concentration was determined by BCA protein assay kit
(Pierce). Each lane was loaded with 20 mg samples. Blots were
probed with the indicated antibodies and immune complexes were
detected by enhancement chemiluminescence (Amersham Phar-
macia Biotech). A Kodak Image Station 440CF with 1-D software
was used for densitometric quantitation.
Bio-Plex Kinase Assay
Antibodies directed against phosphorylated and non-phosphor-
ylated forms of IkB, which were covalently coupled to internally
dyed beads, were purchased from Bio-Rad (Hercules, CA) and
added to a 96 well plate. Protein lysates from treated astrocytes
were added to each well and the target kinases reacted with the
coupled beads. After a series of washes to remove unbound
protein, biotinylated antibodies specific for the phosphorylated
and the non-phosphorylated forms of IkB were added to the
reaction. Next, streptavidin-phycoerythrin (streptavidin-PE) was
added to visualize the biotinylated antibodies on the bead surface.
Data from the reaction were acquired using the Bio-Plex
suspension array system, a dual-laser, flow cytometry-based
microplate reader system (Bio-Rad, Hercules, CA). Data was
presented as the ratio of p-IkB:IkB, fluorescence signals obtained
using Bio-Plex Manager
TM software (Bio-Rad).
Immunocytochemistry
After treatment, cells were fixed in 4% paraformaldehyde,
permeabilized with 0.1% Triton-X, 0.1% BSA in PBS, and blocked
with 1.5% goat serum in PBS (15 min. each procedure). Cells were
incubated with anti-p65(RelA) monoclonal antibodies for 1 h at
room temperature, followed by incubation with goat anti mouse Cy3
(Jackson Immunology). Nuclei were stained with 1 mg/ml Hoechst
33258inPBSfor20 min.FluorescentcellswerevisualizedusingZeiss
AxioVision Z1 microscope and Zeiss MRm digital camera.
ELISA
ELISA plates (96-well) were coated with corresponding mouse
antibodies (1–2 mg/ml) overnight at 4uC. Subsequent ELISA steps
were conducted at room temperature. Plates containing the MCP-
1 antibody were blocked with 1% bovine serum albumin (BSA) in
PBS, while plates containing the IL-6 and TNF-a antibody were
blocked with 1% BSA plus 5% sucrose in PBS for 1 h. Following 3
washes, each plate was incubated with culture supernatants and a
series of dilution standards for 2 h. Capture antibody was added to
each plate and incubated for 90 min. Horseradish peroxidase
(1:4000) was added to TNF-a and IL-6 coated plates, and each
plate was incubated for 20 min. Tetramethylbenzidine substrate
(BD Pharmingen) was then added for color development and
microplates were read at 450 nm using Victor 3 plate reader
(PerkinElmer Inc., Waltham, MA, USA) immediately after
terminating the reaction.
Statistical Analyses
Data were analyzed using one or two-way ANOVA. When
significant main effects were identified (P,0.05), Duncan’s
multiple comparisons test was used to compare intergroup
differences. If group variances were determined to be non-
homogeneous, Kruskal-Wallis nonparametric ANOVA and mul-
tiple comparisons test were used to determine whether differences
were statistically significant. Results given are at 6 h after
Tat6morphine exposure unless noted otherwise.
Results
Tat and/or Morphine Modulates the Activity of
Inflammatory and NF-kB/Rel Family Transcription Factors
Exposure to Tat6morphine caused alterations in 90 of the 152
transcription factors collectively surveyed on TranSignal
TM
Opioids HIV Glial Inflammation
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elevated were related to inflammation. Of these, we decided to
pursue c-Rel because it was the only factor that showed
approximate 2-fold increases in DNA binding activity at both 4
(1.9160.13) and 24 h (1.8560.01) following combined Tat and
morphine exposure (Table 1). Unlike the results with combined
treatment, morphine treatment alone suppressed c-Rel DNA
binding activity to levels below the limit of detection at 4 h, but not
at 24 h (0.6360.01) (Table 1). On the other hand, exposure to Tat
by itself transiently augmented c-Rel activity at 4 h (2.4960.58)
with activity returning to control levels by 24 h (0.8760.04)
(Table 1). Of great interest, c-Rel is a member of the NF-kB/Rel
family of transcription factors that are known to be involved in
regulating expression of MCP-1 and other chemokine genes in a
variety of both human and mouse tissues [38,39] including
astrocytes [40].
NF-kB Inhibition Reduces Proinflammatory Cytokine and
Chemokine Production
To provide evidence that NF-kB regulates MCP-1, IL-6 and
TNF-a production in astrocytes stimulated with HIV-1 Tat6
morphine, cultures were pretreated with the NF-kB inhibitor,
parthenolide. The anti-inflammatory sesquiterpene lactone,
parthenolide, is known to impair the activity of NF-kB by binding
directly to and inhibiting the IkB kinase (IkK) complex, thereby
preventing the degradation of the inhibitory protein, IkB [41,42].
Parthenolide was diluted in culture medium and added to cells at
different concentrations 15–20 min prior to the addition of Tat
and morphine, either alone or in combination. Pretreatment with
both 10 mM and 20 mM parthenolide inhibited Tat6morphine-
induced increases in TNF-a, MCP-1, and IL-6 release at 12 h
(Fig. 1A,C,E). The 12 h time point was chosen to better show that
parthenolide causes a sustained diminution in cytokine secretion.
Real time-PCR detection of MCP-1, IL-6 and TNF-a mRNA
showed that pre-treatment with 20 mM parthenolide completely
abolished cytokine mRNA levels—irrespective of the Tat or
morphine treatment at 24 h (Fig. 1B,D,F). The 24 h time point
was chosen to better show that parthenolide at higher concentra-
tions causes a sustained diminution in mRNA levels. We also
noted that the lower concentrations of parthenolide reduced
MCP-1, IL-6 and TNF-a release, but only partially inhibited IL-6
and MCP-1 mRNA levels, suggesting the possibility that TNF-a
triggers the subsequent release of MCP-1 and IL-6 [43]. NF-kB
activation is accompanied by nuclear translocation and upregula-
tion of DNA binding activity. The translocation of NF-kBi s
usually dependent on the phosphorylation and degradation of
IkBa. To verify that IkBa is phosphorylated in our cell culture
system, astrocytes were treated with Tat alone or in combination
with morphine for 30 min, 2 or 6 h. As shown in Fig. 2A,
exposure to Tat caused an initial burst of IkBa phosphorylation at
30 min that gradually declined to levels similar to Tat combined
with morphine at 6 and 12 h. Indeed, 6 and 12 h time points were
chosen because we found cytokine release is most pronounced
during this time in our culture supernatant. Treatment with
morphine alone did not affect IkBa levels compared to control
cultures, suggesting that Tat alone was responsible for increasing
IkBa phosphorylation. Next, to determine whether down
regulation of MCP-1, IL-6 and TNF-a by parthenolide is
mediated through the sustained inhibition of DNA-binding
activities of NF-kB factors, nuclear extracts from cells treated
with or without the inhibitor for 24 h were subjected to
electrophoretic mobility shift assay (EMSA) (Fig 2B). Parthenolide
treatment markedly decreased NF-kB (p50/p65), p50 homodimer,
and c-Rel DNA binding activity compared to cells that lacked the
inhibitor. Binding specificity was tested using unlabeled wild type-
and mutant kB-oligonucleotides as competitors. Wild type kB
oligonucleotide, but not mutant oligonucleotide, blocked forma-
tion of all three complexes (data not shown). Parthenolide largely
blocked NF-kB transcriptional activity, which leads to a reduced
cytokine release. The data suggest that transient increases in the
activation of NF-kB are required for Tat6morphine-induced
increases in cytokines.
Tat6Morphine Triggers NF-kB/p65 Nucleocytoplasmic
Shuttling
The NF-kB complex must shuttle into the nucleus before it can
influence transcription. NF-kB shuttling has been shown to be
involved in triggering chemokine production in astrocytes [31]. To
determine the extent to which Tat6morphine affected the rate of
NF-kB nuclear translocation and cytokine gene expression in our
system, astrocytes were pretreated with a nuclear export inhibitor,
leptomycin B (LMB), and the effects of HIV-Tat6morphine were
assessed at 30 min, 2 and 6 h. Treatment with Tat alone or in
combination with morphine caused time-dependent increases in
the percentage of cells expressing p65 (RelA) within their nuclei as
compared to vehicle (control) or morphine-treated cells (Fig. 3 A).
A ratio was determined by counting every GFAP
+ cell containing
the p65 in the nucleus divided by the total number of cells (Fig. 3B).
As expected, in astrocytes pretreated with 20 nM LMB, we
observed that with longer treatment times an increasing
percentage of cells retained nuclear p65 (RelA), until only trace
amounts of p65 were detected in the cytoplasm (Fig. 3 A–B).
Cytokine secretion was also affected by LMB. Supernatants from
astrocytes treated with Tat6morphine showed a significant
decrease in MCP-1 IL-6 and TNF-a (Fig. 3C–E), in the presence
of LMB. Moreover, cytokine release was inhibited despite the
retention of the p65 (RelA) subunit in the nucleus. These data
imply that NF-kB enters the nucleus and functions in cytokine
production, and that continued recycling of NF-kB is necessary for
sustained cytokine transcription and expression. Thus, we propose
that combined Tat and morphine cause a sustained cytokine
expression/release in astrocytes through the sustained phosphor-
ylation of p65 (RelA) and enhanced nucleocytoplasmic shuttling of
NF-kB.
[Ca
2+]i Chelation Abrogates Tat6Morphine Induced
Cytokine Release by Astrocytes
To determine whether upsurges in [Ca
2+]i affected Tat6mor-
phine-induced cytokine release by astrocytes, [Ca
2+]i was buffered
Table 1. Effects of morphine and/or Tat on c-Rel DNA
binding activity in striatal astrocytes after 4 or 24 h
continuous exposure.
Treatment DNA binding activity (fold-change from control)
Morphine Tat Morphine +Tat
4 h not detected 2.4960.58 1.9160.13*
24 h 0.6360.01 0.8760.04 1.8560.01*
*P,0.05; significant changes in c-Rel DNA binding activity were noted at 4 h or
24 h following morphine and/or Tat treatment using Kruskal-Wallis
nonparametric ANOVA.
Values represent the mean6SEM of the fold-change in transcription factor
binding relative to control astrocytes.
doi:10.1371/journal.pone.0004093.t001
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BAPTA/AM. Astrocytes were pretreated with varied concentra-
tions of Ca
2+ or the Ca
2+ chelator BAPTA/AM in the medium for
20 min followed by incubation with Tat6morphine for up to 6 h.
Stimulation with Tat alone or in combination with morphine led
to increases in MCP-1, IL-6 and TNF-a production compared
with untreated controls (Fig 4A–C). Pretreatment with 1 or 5 mM
BAPTA/AM partially inhibited MCP-1 and IL-6, while BAPTA/
AM at 10 mM completely abolished production of morphine and
Tat-induced increases in MCP-1, IL-6 and TNF-a. This suggests
Figure 1. Effects of parthenolide on Tat6morphine-induced increases in MCP-1, IL-6 and TNF-a protein and mRNA levels. Astrocytes
were pretreated with 10 or 20 mM of the NF-kB inhibitor, parthenolide (PAR), for 15–20 min followed by incubation with HIV-Tat6morphine (Morph
or MOR) for 12 h (A,C,E) or 24 h (B,D,F). Parthenolide exposure inhibited Tat6morphine-induced increases in the release of MCP-1, IL-6, and TNF-a by
ELISA at 12 h (A,C,E). Parthenolide exposure (20 mM) caused a significant and sustained reduction in Tat-induced increases in MCP-1, IL-6, and TNF-a
mRNA levels at 24 h—that was largely unaffected by coadministering morphine (B,D,F). Values are given as the mean6SEM and representative of at
least 3–5 independent experiments (*P,0.05 vs. vehicle-treated controls;
bP,0.05 vs. controls or Tat6morphine treatment without PAR;
#P,0.05 vs.
Tat6morphine treatment without PAR;
1P,0.05, vs. Tat+morphine-treated cells exposed to vehicle or 20 mM PAR).
doi:10.1371/journal.pone.0004093.g001
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than MCP-1 and IL-6, and further implicates TNF-a as a trigger
in the release of other cytokines. Furthermore, the release of MCP-
1 and IL-6 is highly calcium-dependent. Next, Ca
2+ was added
exogenously to each well, and increasing Ca
2+ concentration
outside the cell ([Ca
2+]o), markedly augmented Tat6morphine-
evoked MCP-1 and IL-6, but not TNF-a release (Fig. 5A–C).
Again in this experiment, TNF-a was less affected by changes in
[Ca
2+]i compared to MCP-1 and IL-6. Interestingly, however,
increasing [Ca
2+]i by itself is not sufficient to increase cytokine
release. Despite increases in [Ca
2+]i, morphine treatment alone did
not increase cytokine release suggesting that an additional signal
independent from Ca
2+, such as the phosphorylation of NF-kBo r
I-kappa-B-kinase (IKK), must also occur in concert with increases
in [Ca
2+]i. Thus, while increasing [Ca
2+]i may be necessary, it is
not sufficient to induce cytokine release by astrocytes. Collectively,
our findings suggest that Tat alone is sufficient to trigger the
[Ca
2+]i-dependent signal and NF-kB activity, while morphine is
not. However, in combination with Tat, morphine can modulate
Tat-induced cytokine release through a Ca
2+-dependent mecha-
nism involving the NF-kB pathway.
Inhibition of IkBa Degradation and NF-kB-Dependent
Cytokine Expression in Astrocytes
Next, we investigated whether the association with IkBa
regulates the activity of NF-kB and cytokine production in our
system. We used Ro106-9920 to target the ubiquitination of IkBa
and inhibit the dissociation of NF-kB/IkBa complex [44], and
prevent the nuclear import of NF-kB. Astrocytes were pretreated
with Ro106-9920 for 15–20 min prior to the addition of Tat,
morphine, or Tat plus morphine for 6 h. Ro106-9920 (10 mM)
treatment significantly decreased Tat6morphine-evoked cytokine
release by astrocytes, highlighting the important role of NF-kBi n
cytokine secretion (Fig. 5A–C). Next, it was determined whether
inhibiting the dissociation of the NF-kB/IkBa complex could still
attenuate Tat-induced cytokine increases, even in the presence of
high levels of Ca
2+. Despite increases in [Ca
2+]i (induced by
treating astrocytes with 5 mM Ca
2+), inhibiting the activation of
NF-kB completely prevented Tat6morphine-induced increases in
cytokine release (Fig 5 A–C; Cal+RO). No changes in cytokine
production were seen in astrocytes treated with BAPTA/AM or
with BAPTA/AM+Ro106-9920 (Fig 5 A–C), suggesting that the
IkBa-NF-kB complex is located downstream of Ca
2+ signaling
events. Cytotoxicity was not observed in astrocytes with any of the
above treatments after 2–6 h incubation (not shown). Altogether,
these results suggest that the degradation of IkB proteins is
necessary for NF-kB nuclear translocation and cytokine gene
upregulation in astrocytes treated with Tat6morphine. Moreover,
the fact that Ro106-9920 blocked cytokine release even in the
presence of high [Ca
2+]i suggests a strong involvement of NF-kB,
and imply that once this pathway is shut down it is virtually
impossible to generate cytokines irrespective of Ca
2+.
Ca
2+ Transiently Induces NF-kB Activation and Nuclear
Translocation
Lastly, we investigated whether Ca
2+ chelation interferes with
Tat6morphine-induced NF-kB activation and nuclear transloca-
tion. Astrocyte cultures were pretreated with vehicle (culture
medium), BAPTA/AM (10 mM), or excess Ca
2+ outside (5 mM),
for 15–20 min before exposure to vehicle, morphine (Morph) or
Tat6morphine for 30 min, or 1, 2, or 4 h. The proportion of
astrocytes stained with p65 (RelA)-immunoreactive nuclei was
then determined. Tat6morphine markedly increased the translo-
cation of the p65 (RelA) subunit of NF-kB into the nucleus of
Figure 2. Tat phosphorylates IkBa in astrocytes. To verify that IkBa is phosphorylated in our cell culture system, astrocytes were treated with
Tat alone or in combination with morphine for 30 min, 2 and 6 h (A). Increases in IkBa phosphorylation were noted in cell lysates treated with
Tat6morphine at 30 min compared to treatment with vehicle or morphine alone (*P,0.05 vs. controls at 30 min). After 6 h, the amount of
phosphorylated IkBa was equal in cell lysates treated with Tat alone or Tat plus morphine (A). Down regulation of NF-kB (p65), c-Rel and p50
by parthenolide. Nuclear extracts from cells treated with or without Tat6parthenolide for 24 h were subjected to electromobility shift assay
(EMSA) with labeled NF-kB oligonucleotide (B). Nuclear extracts containing parthenolide showed a down regulation in NF-kB DNA binding activity as
compared to the DNA binding activity of nuclear extract without parthenolide.
doi:10.1371/journal.pone.0004093.g002
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PLoS ONE | www.plosone.org 7 December 2008 | Volume 3 | Issue 12 | e4093Figure 4. Effects of BAPTA on Tat6morphine-induced cytokine release by astrocytes. Buffering [Ca
2+]i blocked Tat6morphine (Morph or
MOR) induced cytokine release by astrocytes at 6 h. Stimulation with Tat6morphine caused significant increases in MCP-1, IL-6, and TNF-a
production compared with untreated controls (A–C). The Ca
2+ chelator BAPTA caused significant, concentration-dependent reductions in the release
of MCP-1, IL-6 and TNF-a by astrocytes. Results are representative of 3 independent experiments, and the data are given as the mean6SEM at 6 h
(*P,0.05 vs. vehicle-treated controls;
#P,0.05 vs. identical treatment without BAPTA).
doi:10.1371/journal.pone.0004093.g004
Figure 3. Tat6morphine-induced alterations in cytoplasmic-nuclear shuttling of the p65 subunit of NF-kB regulate cytokine
production by astrocytes. Cells were pretreated with vehicle or leptomycin B (LMB) followed by 30 min, 2 or 6 h treatment (only data at 2 h are
shown) with Tat6morphine (Morph) and analyzed by immunofluorescence microscopy to determine the proportion of GFAP (red fluorescence) cells
with p65(RelA; green fluorescence) subunit present within their nuclei (labeled with Hoechst 33258; blue fluorescence) (A). GFAP
+ cells containing
p65 in the nucleus were counted and divided by the total number of GFAP
+ cells (B). Tat alone or in combination with morphine increased the
trafficking of the p65(RelA) subunit of NF-kB into the nucleus (A–B), while blocking nuclear export with LMB increases the accumulation of p65(RelA)
subunits in the nucleus (A–B; *P,0.05 vs. vehicle-or LMB-treated controls;
1P,0.05 vs. vehicle-treated controls;
{P,0.05 vs. Tat6morphine treatment
without LMB). (C–E): LMB attenuates cytokine release caused by Tat6morphine. Analysis of astrocyte conditioned medium by ELISA showed a
significant decrease in MCP-1, IL-6 and TNF-a production in astrocytes pretreated with LMB (*P,0.05 vs. vehicle or LMB-treated controls lacking
Tat6morphine;
#P,0.05 vs. Tat+morphine treated astrocytes without LMB). Data represent the mean6SEM of 3 separate experiments at 6 h.
doi:10.1371/journal.pone.0004093.g003
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2+ with BAPTA significantly
attenuates p65 (RelA) nuclear entry in vehicle (control), morphine,
or Tat6morphine exposed astrocytes (Fig. 6). Conversely, adding
excess extracellular Ca
2+ accelerated translocation of p65 (RelA)
into the nucleus in all treated groups. The effects were time-
dependent and the combined effects of Tat and morphine were
more robust than those seen with Tat alone. Detection of p65
(RelA) in the nuclei of about 5% of astrocytes at 30 min and the
ability of BAPTA/AM to markedly reduce p65 (RelA) nuclear
labeling in vehicle-treated control cultures suggested that p65
(RelA)/NF-kB was being tonically activated at low levels in our
cell cultures. Buffering [Ca
2+]i with BAPTA/AM significantly
delays nuclear import, while artificially elevating Ca
2+ by excessive
(5 mM) Ca
2+ outside the cell accelerates p65 (RelA) subunit
trafficking into the nucleus. Note that some p65 (RelA) nuclear
shuttling occurs in vehicle-treated astrocytes suggesting that tonic
levels of nucleocytoplasmic shuttling occur and that other events
such as the phosphorylation of specific NF-kB subunits are
operative (Fig. 6). Thus, calcium affects p65 (RelA)/NF-kB activity
by modulating its trafficking into the nucleus.
Figure 6. Ca
2+ modulates morphine and/or HIV-1 Tat-induced trafficking of the p65 (RelA) subunit of NF-kB into the nucleus of
astrocytes. Chelating [Ca
2+]i with 10 mM BAPTA significantly delays Tat and/or morphine-(Morph or MOR) induced nuclear import of p65(RelA),
while artificially elevating [Ca
2+]i by excessive (5 mM) Ca
2+ outside the cell ([Ca
2+]o), accelerates p65 subunit trafficking into the nucleus. Note that p65
nuclear shuttling occurs both in vehicle and in BAPTA-treated astrocytes, suggesting that nucleocytoplasmic shuttling occurs continuously. It also
infers that other events such as the phosphorylation of specific NF-kB subunits are operative (
1P,0.05, vehicle vs. BAPTA -treated cells;
{P,0.05,
control vs. 5 mM [Ca
2+]o-treated cells).
doi:10.1371/journal.pone.0004093.g006
Figure 5. Blocking NF-kB nuclear import prevents Tat6morphine-induced cytokine release by astrocytes (A–C). Astrocytes were
pretreated with Ro106-9920 (RO; 10 mM), which prevents the import of NF-kB into the nucleus, for 15 min followed by the addition of Tat6morphine
for up to 6 h. RO exposure significantly decreased Tat6morphine-evoked cytokine release by astrocytes. In addition, RO attenuated Tat-induced
increases in the presence of high levels of Ca
2+, which is induced by treating astrocytes with 5 mM Ca
2+ outside the cell ([Ca
2+]o). Despite increases in
Ca
2+, preventing the import of NF-kB into the nucleus completely prevented Tat6morphine-induced increases in cytokine release (*P,0.05 vs.
vehicle-treated controls;
bP,0.05 vs. control, morphine, or Tat+morphine-treated controls;
1P,0.05, vehicle vs. 5 mM [Ca
2+]o-treatment;
#P,0.05 vs.
Tat6morphine treatment without RO, BAPTA, or 5 mM [Ca
2+]o).
doi:10.1371/journal.pone.0004093.g005
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Our previous data showed that opiates can exacerbate the release
of cytokines in HIV-1 Tat protein exposed astrocytes [17]. The
interactive effects are time-dependent, differ among affected
cytokines, and mediated through m-opioid receptor-expressing
subpopulations of astrocytes. We also showed that m opioid receptor
activation or exposure to Tat increased Ca
2+, while causing
synergistic increases in [Ca
2+]i in combination [17]. Prior studies
indicated that morphine elevated [Ca
2+]i in astrocytes through
several different pathways including influx through voltage-
dependent L-type Ca
2+ channels and mobilization through IP3-
dependent pools, with subsequent Ca
2+-induced Ca
2+ release
(CICR or regenerative Ca
2+) from internal stores [37]. Based on
long-standing evidence of the involvement of NF-kBi nt h e
production of inflammatory mediators, we predicted that opiates
would potentiate the effects of HIV-1 Tat on proinflammatory
cytokineproduction byastrocytes throughsignals converging atNF-
kB. To test this hypothesis, we examined whether exposure to HIV-
1 Tat6morphine modulates the activation of NF-kB and whether
this in turn was responsible for IL-6, TNF-a, and MCP-1 by
astrocytes.Inaddition,wealsoexplored theextenttowhichTatand
opiate-inducedchangesin[Ca
2+]imodulateactivationoftheNF-kB
pathway. In the present study, Tat6morphine increased IkBa
phosphorylation, the rate of p65 translocation into the nucleus, and
NF-kB binding by EMSA, while the NF-kB inhibitor parthenolide
eliminated cytokine release in Tat6morphine treated astrocytes. In
addition, manipulating [Ca
2+]i modified both Tat6morphine-
evoked p65/NF-kB trafficking into the nucleus and cytokine release
to a significant extent. Chelating [Ca
2+]i prevented Tat6morphine-
induced p65/NF-kB nuclear translocation and cytokine release,
while increasing [Ca
2+]i above baseline levels exacerbated these
effects. Taken together, the results suggest that Tat induces cytokine
production by astrocytes through a pathway dependent on [Ca
2+]i,
NF-kB nuclear translocation and transcriptional activity, while
morphine appears to enhance the effects of Tat through a
convergent signal involving [Ca
2+]i and the subsequent rate of
p65/NF-kB shuttling in to the nucleus.
Based on data from this study, we propose that Tat increases
cytokine production because it can both elevate [Ca
2+]i and
activate NF-kB. The addition of exogenous calcium increases
intracellular calcium, after functionally depleting energy-depen-
dent calcium pumps, and overfilling of endoplasmic reticulum
(ER) (and other, including nuclear stores), an overfilling of ER
stores would likely boost the ability of Tat to induce cytokine
release. Therefore, Tat is sufficient for cytokine release by
astrocytes. Opiates alone are not sufficient to drive increases in
cytokine release because they do not appear to activate NF-kBi n
astrocytes. In fact, morphine fails to act even when [Ca
2+]i is
artificially elevated by high levels of extracellular Ca
2+. Opiates,
however, can potentiate the effects of Tat through further
increases in [Ca
2+]i at sites upstream of NF-kB (summarized in
Fig. 7). We speculate that increases in [Ca
2+]i are accompanied by
aC a
2+-independent signal that likely involves the phosphorylation
and targeted ubiquitination of IkBa, which frees NF-kB allowing it
to translocate into the nucleus.
Studies using the Ca
2+ chelator BAPTA/AM provide circum-
stantial evidence that [Ca
2+]i modulate NF-kB activity. The
possible regulation of NF-kB pathway by Ca
2+ signaling was
indirectly implied in studies showing that release of MCP-1, IL-6
and to a lesser extend TNF-a was adversely affected by the Ca
2+
chelator BAPTA. To explore whether Ca
2+ affects the activation
and translocation of NF-kB, we incubated astrocytes with
BAPTA/AM followed by treatment with Tat6morphine. BAPTA
significantly reduced MCP-1 and IL-6 expression in a concentra-
tion-dependent manner while production of TNF-a was reduced
but only at the highest concentration of BAPTA, inferring
differential thresholds of Ca
2+ sensitivity for TNF-a versus
MCP-1 and IL-6. Alternatively, it may be possible that TNF-a
serves as an initiator of cytokine release. In fact, others have shown
that RANTES stimulates the release of TNF-a which subsequently
participates in the amplification of the astrocyte inflammatory
cascade by stimulating MCP-1 production [16,45]. Interestingly,
we previously found that morphine could exacerbate Tat-induced
increases in the release of RANTES and MCP-1, but not TNF-a,
by striatal mouse astrocytes [17]. The discrepancies in the data
might be explained by differences in the techniques used to detect
cytokines (Pananomics/Raybio antibody arrays vs. ELISA) or
differences in the phenotype and composition of astrocyte-
enriched cultures obtained from postnatal day 0–1 vs. postnatal
day 4 mice. For example, the proportion of microglia and
oligodendroglia increase, while the percentage of glial precursors
decreases with maturation. Collectively, the results suggest that
TNF-a production is regulated differently from MCP-1 and IL-6
and differs in its response to morphine. Moreover, we found that
buffering [Ca
2+]i reduced the trafficking of the p65 (RelA) subunit
of NF-kB and reduced Tat6morphine-induced increases in p65
nuclear translocation. The results of our data imply that [Ca
2+]i
can regulate the activation and nuclear translocation of NF-kB.
Our results agree with findings by others that the induction of NF-
kB activity can be regulated by Ca
2+, and that Ca
2+ oscillations
increase the efficiency and specificity of the expression of various
genes [46]. Lilienbaum and Israe ¨l [47] showed that transcriptional
activity of NF-kB in primary neurons can be regulated by a
complex network, involving Ras, PI3K, and Akt, all of which are
controlled by Ca
2+. Their results show that instead of a single
signaling pathway, NF-kB activity in neurons is regulated by
integrated cross talk of multiple transduction cascades.
The specific pathway(s) by which Ca
2+ is activated in astrocyte
cultures following treatment with Tat alone or in combination
with morphine is unclear. One possibility is that BAPTA
suppresses the activation of NF-kB by buffering cytoplasmic
Ca
2+ increases that are necessary for the phosphorylation of IkK.
Although we cannot say whether the Ca
2+ increases originate from
internal stores and/or influx of extracellular Ca
2+ [37], it is
possible that the signal involves the convergence of multiple
independent Ca
2+ pathways. For example, dantrolene can modify
Tat and morphine-evoked cytokine release (El-Hage, unpublished)
suggesting that CICR propagates that signal. Alternatively, Ca
2+
mobilization via IP3-dependent internal stores or Ca
2+ influx via
L-type Ca
2+ channels could be potentially involved since both are
independently affected by morphine [37] or Tat [48,49].
NF-kB activity can be regulated at several levels, including
through alterations in cytoplasmic-nuclear shuttling. To assess the
role of trafficking, we pretreated astrocytes with a nuclear export
inhibitor, leptomycin B (LMB). LMB at a low concentration is a
potent and specific inhibitor of many proteins including the HIV-1
Rev protein, MAPK/ERK, and the nuclear export protein CRM1
[50,51]. In the present study, treatment with LMB blocked
cytokine production, despite the continued presence of nuclear
p65 (RelA), indicating that NF-kB turnover is essential for cytokine
release by astrocytes exposed to Tat6morphine. Our data agrees
with others who have shown that NF-kB shuttling is a mechanism
that is involved in the induction of chemokines in astrocytes [31],
and appears to constitutively occur at low levels even in non-
activated cells [52]. The small molecule, Ro106-9920, was used to
further investigate the signal transduction mechanism involved in
NF-kB-induced cytokine production in astrocytes treated with
Opioids HIV Glial Inflammation
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cytokine release from Tat or Tat plus morphine-treated astrocytes,
since this molecule is known to inhibit IkBa ubiquitination and
thereby prevent NF-kB dimers from forming and translocating
into the nucleus. Our results indicate that IkBa ubiquitination is
essential for nuclear translocation of the NF-kB dimeric complex
leading to the regulation of cytokine production.
TNF-a and IL-1 trigger a classical pathway involving the
activation of the IKK complex leading to the phosphorylation and
then the ubiquitination and degradation of IkBa, allowing NF-kB
to translocate to the nucleus. This pathway is crucial for the
activation of innate immunity and inflammation [29,53], although
alternative pathways have been proposed [33]. NF-kB activation
can also be modulated by G-protein coupled receptors such as the
m opioid receptor through a variety of upstream events including
the cAMP/PKA/CREB, PI3K/Akt/IKK and PLC/PKC/IkK
pathways [54]. Moreover, increased reactive oxygen species (ROS)
can activate NF-kB. Once primed by oxidative stress, increases in
[Ca
2+]i can exacerbate NF-kB transcriptional activity [55], which
is similar to our preliminary findings in astrocytes and infers that
Ca
2+-dependent increases in ROS could mediate the effects of
Tat6morphine. Preliminary data indicates that morphine signif-
icantly increases oxyradical production in Tat-exposed astrocytes.
It is important to emphasize that NF-kB can serve dramatically
distinct functions in different neural cell types. For example, while
NF-kB activation in immune cells such as macrophages/microglia
herald inflammation, oxyradical production, and cell stress, NF-
kB-dependent transcription in neurons has entirely different
consequences promoting synaptic plasticity, [Ca
2+]i homeostasis,
and prolonged viability [56–58]. For this reason, it may be an
overgeneralization to assume that NF-kB functions are the same in
astrocytes and macrophages/microglia despite superficial similar-
ities in cytokine release. Furthermore, the consequences of m
opioid receptor activation are so dissimilar in astrocytes from other
cell types [59], that it would be challenging to predict the nature of
converging opiate-Tat toxic signals without empirical testing in
astrocytes. Therefore, additional studies are needed to clarify a
potential relationship between elevated Ca
2+, ROS, the potential
inhibition of proteasome proteolysis, and NF-kB transcriptional
activity in astrocytes.
Irrespective of the exact mechanisms involved, here we show
that exposure to Tat alone increases IkB phosphorylation/
Figure 7. Proposed model for the involvement of NF-kB signaling in the regulation of cytokine and chemokine in Tat6morphine
treated astrocytes. Arrows indicate activation of the signaling pathway; the ‘‘I’’ signs indicate pathway inhibition. Exposure to Tat alone increases
IkB phosphorylation/degradation and NF-kB transcriptional activity, and additionally increases [Ca
2+]i in astrocytes [48]. Although morphine
treatment alone fails to significantly activate NF-kB in astrocytes, in combination with Tat it can potentiate Tat-induced increases in [Ca
2+]i at sites
upstream of NF-kB [37]. How [Ca
2+]i affects IkB degradation in the present study is uncertain (?), but may involve increased oxidative stress [55], and
decreased proteasome activity.
doi:10.1371/journal.pone.0004093.g007
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increasing [Ca
2+]i in astrocytes [48]. On the other hand, morphine
treatment alone fails to significantly activate NF-kB in astrocytes,
and causes modest increases in [Ca
2+]i. However, morphine in the
presence of Tat potentiates Tat-induced cytokine release by
increasing [Ca
2+]i at sites upstream of NF-kB, which increases NF-
kB activation and cytokine production. The unique proinflamma-
tory response of astroglia to combined Tat and morphine
exposure, which is mediated by NF-kB and modified by changes
in Ca
2+ homeostasis, might explain why the CNS is especially
vulnerable to the combined effects of opiate abuse and human
immunodeficiency virus encephalitis (HIVE) [60]. Although
additional studies are needed to determine how Ca
2+ modulates
NF-kB activation, our results suggest that astrocytes are significant
in orchestrating the deleterious effects of opiate abuse in the CNS
of HIV-1 infected individuals.
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